Literature DB >> 9915462

Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy.

N Shimizu1, H Masuda, H Yamanaka, N Oriuchi, T Inoue, K Endo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9915462

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  3 in total

1.  Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.

Authors:  Mehmet Asim Bilen; Marcella M Johnson; Paul Mathew; Lance C Pagliaro; John C Araujo; Ana Aparicio; Paul G Corn; Nizar M Tannir; Franklin C Wong; Michael J Fisch; Christopher J Logothetis; Shi-Ming Tu
Journal:  Cancer       Date:  2014-08-22       Impact factor: 6.860

2.  Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer.

Authors:  Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04       Impact factor: 9.236

Review 3.  Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer.

Authors:  Shi-Ming Tu; Sue-Hwa Lin; Donald A Podoloff; Christopher J Logothetis
Journal:  Clin Adv Hematol Oncol       Date:  2010-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.